92017-04-4

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 2365-48-2 Methyl thioglycolate 
• 99-90-1 para-bromoacetophenone 
• 32361-73-2 1-(4-methansulfinylphenyl)ethanone 
• 96-32-2 bromoacetic acid methyl ester 
• 1778-09-2 4-(Methylthio)acetophenone 
• 13329-40-3 4-Iodoacetophenone 

Downstream Products

• 17067-15-1 (4-acetyl-phenylsulfanyl)-acetic acid 
• 460087-63-2 1-[3-(3,5-Diisopropyl-2-methoxymethoxy-phenyl)-benzo[b]thiophen-5-yl)-ethanone 

Relevant academic research and scientific papers

L-proline-promoted CuI-catalyzed C-S bond formation between aryl iodides and thiols

An improved, mild procedure for the CuI-catalyzed coupling reactions of aryl iodides with aliphatic and aromatic thiols, using L-proline as the ligand, is reported. This procedure is noteworthy given its high generality and exceptional level of functional group toleration. Copyright Taylor & Francis Group, LLC.

Sulfoxide Reduction/C(sp3)-S Metathesis Cascade in Ionic Liquid

A sulfoxide reduction/C-S bond metathesis cascade between sulfoxides and alkyl bromides has been developed to access high-value sulfides without the use of any catalysts or bases. In this cascade, classical Kornblum oxidation is employed to reduce sulfoxides with alkyl bromides in ionic liquid. This protocol features high functional tolerance, mild conditions, promising scalability, and sustainable solvents.

Fibrinogen receptor antagonists and their use

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

Design and synthesis of benzofused heterocyclic RXR modulators

Benzofused heterocyclic analogs of the RXR selective modulator 1 (LG101506) were synthesized, and tested for their ability to bind RXRα and activate RXR homo and heterodimers. Potency and efficacy were observed to be dependent upon the choice of heterocycle as well as the sidechain employed.

Retinoid x receptor modulators

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.